Gluten-free food supply
New Clinical Policy – Gluten Free:
The new clinical policy for Gluten Free prescribing has been finalised and formally approved by the HNY ICB Executive.
To view the policy and supporting documents, please click here.
This policy should now be applied as follows:
Key points
From 1 March 2026 onwards, there should be no new initiation of GF product prescribing except for patients who meet the policy’s exclusion criteria.
For all existing GF product repeat prescribing, a review should take place within the next few months, so that as of 01 May, all repeat prescribing is in line with the new policy.
Supporting documents include:
- A statement which can be shared with patients, describing the rationale for the change in policy and highlighting that this is a decision that has been made by the ICB not the prescriber.
- An updated guide to providing a good quality annual review for people who require a gluten free diet.
- Other supportive information including links to support groups and information about naturally gluten free products and healthy eating.
The ICB will be reviewing the prescribing data at 1-3 and 6-months post implementation as part of their approach to monitoring impact.
Gluten Free prescribing guidelines by area can be seen below:
